Irinotecan Fresenius Kabi (Irinotecan Hydrochloride Trihydrate)

After infusion, irinotecan is metabolised to SN‑38, which binds to the DNA‑topoisomerase I complex. This prevents the re‑ligation of single‑strand DNA breaks during replication, leading to accumulation of DNA damage and ultimately causing tumor‑cell death.

The specific dose of Irinotecan Fresenius Kabi is determined by the prescribing oncologist based on the patient’s clinical condition, body surface area, and treatment protocol. Dosing regimens are individualized and should follow the latest clinical guidelines.

Irinotecan is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It is contraindicated in pregnant women and should not be used while breastfeeding because it can be excreted in milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, offering a distinct mechanism from fluoropyrimidines or oxaliplatin. It is often combined with these agents to enhance response rates. Compared with other topoisomerase inhibitors, irinotecan has a well‑characterised toxicity profile that includes notable diarrhea and neutropenia.

Irinotecan Fresenius Kabi should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Prior to use, the solution should be inspected for particulate matter and any discoloration before administration.

The medication is supplied as an injectable solution for intravenous infusion. It is typically infused over a period of 90 minutes under medical supervision, with appropriate pre‑medication to manage nausea, vomiting and other infusion‑related reactions.

The most serious adverse events include severe neutropenia, febrile neutropenia, life‑threatening diarrhea or colitis, intestinal perforation, and rare allergic reactions such as anaphylaxis. Patients should be monitored closely for signs of infection, gastrointestinal toxicity and hepatic dysfunction.

Irinotecan is contraindicated in patients with known hypersensitivity to the drug or its excipients, in pregnant women, and in individuals with severe hepatic impairment without dose adjustment. Caution is also advised for patients with pre‑existing bone‑marrow suppression or uncontrolled infections.